- Home
- LTRN vs FGEN Comparison
LTRN vs FGEN Comparison
Compare LTRN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- FGEN
- Stock Information
- Founded
- LTRN 2013
- FGEN 1993
- Country
- LTRN United States
- FGEN United States
- Employees
- LTRN N/A
- FGEN N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- FGEN Health Care
- Exchange
- LTRN Nasdaq
- FGEN Nasdaq
- Market Cap
- LTRN 38.0M
- FGEN 33.5M
- IPO Year
- LTRN 2020
- FGEN 2014
- Fundamental
- Price
- LTRN $3.73
- FGEN $0.31
- Analyst Decision
- LTRN Buy
- FGEN Strong Buy
- Analyst Count
- LTRN 2
- FGEN 1
- Target Price
- LTRN $25.00
- FGEN $10.00
- AVG Volume (30 Days)
- LTRN 43.8K
- FGEN 899.4K
- Earning Date
- LTRN 05-08-2025
- FGEN 05-05-2025
- Dividend Yield
- LTRN N/A
- FGEN N/A
- EPS Growth
- LTRN N/A
- FGEN N/A
- EPS
- LTRN N/A
- FGEN N/A
- Revenue
- LTRN N/A
- FGEN $29,621,000.00
- Revenue This Year
- LTRN N/A
- FGEN $232.81
- Revenue Next Year
- LTRN N/A
- FGEN $9.16
- P/E Ratio
- LTRN N/A
- FGEN N/A
- Revenue Growth
- LTRN N/A
- FGEN N/A
- 52 Week Low
- LTRN $2.55
- FGEN $0.18
- 52 Week High
- LTRN $7.21
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- LTRN 55.76
- FGEN 46.92
- Support Level
- LTRN $3.00
- FGEN $0.27
- Resistance Level
- LTRN $3.71
- FGEN $0.31
- Average True Range (ATR)
- LTRN 0.36
- FGEN 0.03
- MACD
- LTRN 0.08
- FGEN 0.01
- Stochastic Oscillator
- LTRN 85.51
- FGEN 81.38
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.